Ana Lilia González-Yebra

Dr. Ana Lilia González-Yebra

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ACAndrea Ceja-Fdez
Andrea Ceja-Fdez
RCRamon Carriles
Ramon Carriles
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
JVJuan Vivero-Escoto
Juan Vivero-Escoto
Elder De la Rosa CruzElder De la Rosa Cruz
Elder De la Rosa Cruz
TLTzarara Lopez-Luke
Tzarara Lopez-Luke
In this work, gold NPs were prepared by the Turkevich method, and their interaction with HPV and cancerous cervical tissues were studied by scanning electron microscopy, energy-dispersive x-ray spectroscopy, confocal and multiphoton microscopy and SERS. The SEM images confirmed the presence and localization of the gold NPs inside of the two kinds of tissues. The light absorption of the gold NPs was at 520 nm. However, it was possible to obtain two-photon imaging (red emission region) of the gold NPs inside of the tissue, exciting the samples at 900 nm, observing the morphology of the tissues. The infrared absorption was probably due to the aggregation of gold NPs inside the tissues. Therefore, through the interaction of gold nanoparticles with the HPV and cancerous cervical tissues, a surface enhanced Raman spectroscopy (SERS) was obtained. As preliminary studies, having an average of 1000 Raman spectra per tissue, SERS signals showed changes between the HPV-infected and the carcinogenic tissues; these spectral signatures occurred mainly in the DNA bands, potentially offering a tool for the rapid screening of cancer.

28 April 2024 in Medicina
Verified
Journal Article
Open access
PDF file
Pablo Romero-MorelosPablo Romero-Morelos
Pablo Romero-Morelos
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
LBLuis Jonathan Bueno-Rosario
Luis Jonathan Bueno-Rosario
BGBeatriz Gonzalez-Yebra
Beatriz Gonzalez-Yebra
Background and Objectives: Leukemia, characterized by abnormal leukocyte production, exhibits clonal origin from somatic mutations. Globally, it ranked 15th in cancer incidence in 2020, with higher prevalence in developing countries. In Mexico, it was the ninth most frequent cancer. Regional registries are vital for understanding its epidemiology. This study aims to analyze the prevalence and age-standardized incidence rates of leukemias in a tertiary care hospital in the Mexican Bajio region. Materials and Methods: Leukemia cases from 2008–2018 were analyzed, and 535 medical records were included in this study. The prevalence, distribution, and age-specific incidence rate of different types and subtypes of leukemia were determined according to sex and age groups. Results: Overall, 65.79% consisted of lymphocytic leukemia, 33.64% of myeloid leukemia, and 0.56% of monocytic leukemia. No significant sex-based differences were found, but age-specific patterns were observed. Leukemia distribution by age revealed significant associations. Lymphocytic leukemia dominated in the pediatric population, particularly acute lymphocytic leukemia, while myeloid leukemia shifted towards adulthood. Age-specific incidence patterns showed, first, that lymphocytic leukemia is the most common leukemia in pediatric ages, and second, there is a shift from acute lymphocytic leukemia dominance in pediatric ages to myeloid leukemia incidence in late adulthood, emphasizing nuanced epidemiological dynamics. Conclusions: Acute leukemia cases occurred with high prevalence in our study population, with a high incidence in pediatric and adulthood populations, especially for acute lymphocytic leukemia, showing a (<18 years) 153.8 age-standardized incidence rate in the pediatric group, while in the adult population, the age-standardized rate was 59.84. In the age-specific analysis, we found that the childhood group (5–9 years) were the most affected by acute lymphocytic leukemia in the pediatric population, while in the adult population, the early-adulthood group (15–29 years) were the most affected age group. In contrast, chronic myeloid leukemia affected both adults and the pediatric populations, while chronic lymphocytic leukemia and monocytic leukemia were exclusive to adults. The study underscores the need for tailored diagnostic, treatment, and preventive strategies based on age, contributing valuable insights into the leukemia epidemiology of the Bajio region.

12 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
Pablo Romero-MorelosPablo Romero-Morelos
Pablo Romero-Morelos
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
DMDaniela Muñoz-López
Daniela Muñoz-López
ELElia Lara-Lona
Elia Lara-Lona
BGBeatriz Gonzalez-Yebra
Beatriz Gonzalez-Yebra
Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome and distinct BCR::ABL1 gene transcripts. We assessed the frequencies of these transcripts in Mexico, Latin America, and worldwide. We determined the prevalence of BCR::ABL1 transcripts in CML patients and intercontinental or regional variations using specialized databases and keywords. We analyzed 34 studies from 20 countries, encompassing 5795 patients. Keyword-based searches in specialized databases guided data collection. ANOVA was employed for transcript distribution analysis. The b3a2 transcript was most prevalent globally, followed by b2a2, with e1a2 being the least frequent. Interestingly, Mexico City exhibited a higher incidence of b2a2, while b3a2 predominated in the remaining country. Overall, no significant intercontinental or regional variations were observed. b3a2 was the most common BCR::ABL1 transcript worldwide, with b2a2 following closely; e1a2 was infrequent. Notably, this trend remained consistent in Mexico. Evaluating transcript frequencies holds clinical relevance for CML management. Understanding the frequency of transcript informs personalized CML treatments.

5 December 2025 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
DMDaniela Beatriz Muñoz-López
Daniela Beatriz Muñoz-López
CCCarmen Rosa Rea Campos
Carmen Rosa Rea Campos
ETEloy Mosqueda Tapia
Eloy Mosqueda Tapia
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
DADemetrio Arturo Feria Arroyo
Demetrio Arturo Feria Arroyo
RMRafael Martínez-Sánchez
Rafael Martínez-Sánchez
The population of Mexico is ageing rapidly. Older adults in marginalised areas may be particularly vulnerable to food insecurity, with potential impacts on

2 January 2023 in Salud Pública de México
Verified
Journal Article
Open access
PDF file
BGBeatriz Gonzalez-Yebra
Beatriz Gonzalez-Yebra
FRFrancisco Arath Ruíz-Velázquez
Francisco Arath Ruíz-Velázquez
AHAnaid Herrerías-García
Anaid Herrerías-García
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
ELElia Lara-Lona
Elia Lara-Lona
LALauro Fabian Amador-Medina
Lauro Fabian Amador-Medina

28 April 2024 in Genes
Verified
Journal Article
Open access
PDF file
Pablo Romero-MorelosPablo Romero-Morelos
Pablo Romero-Morelos
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
AHAnaid Herrerías-García
Anaid Herrerías-García
FRFrancisco Arath Ruíz-Velázquez
Francisco Arath Ruíz-Velázquez
LBLuis Jonathan Bueno-Rosario
Luis Jonathan Bueno-Rosario
BGBeatriz Gonzalez-Yebra
Beatriz Gonzalez-Yebra
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.